AI in Drug Discovery Market to Expand by 36.1% CAGR as Popularity of Mindful AI Offers Breakthrough Opportunities, Notes TMR

AI in Drug Discovery Market: Introduction

According to the report, the global AI in drug discovery market was valued at US$ 0.35 Bn in 2020 and is projected to expand at a CAGR of 36.1% from 2021 to 2031. Artificial intelligence (AI) is expected to be a lucrative technology in the healthcare industry. The implementation of AI reduces research and development gap in the drug manufacturing process and helps in targeted manufacturing of drugs. Hence, biopharmaceutical companies are turning to AI to enhance market share. This is a major factor fueling the growth of the global AI for drug discovery market.

The increase in pressure on drug manufacturers to reduce drug prices is another factor expected to boost the growth of the global AI for drug discovery market. Shortage of skilled healthcare personnel is likely to accelerate the growth of the global AI for drug discovery market. However, limited awareness, high cost, and technical limitation of AI decision-making is projected to hamper the growth of the global market. Developing countries such as India and China offer significant opportunities in the AI for drug discovery market.

 Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=82867

Increase in Incidence of Chronic Diseases

The incidence of chronic diseases, including diabetes, chronic obstructive pulmonary disease (COPD), coronary artery disease, arthritis, asthma, hepatitis, and cancer, has increased significantly in major regions across the globe. This can be attributed to increase in the geriatric population across the world (over 20% of the global population is anticipated to be aged over 65 years by 2050), changing lifestyles, and dietary changes due to rapid urbanization.

According to the International Diabetes Federation, in 2019, 463 million people across the world were diagnosed with diabetes. Moreover, the number of new cancer cases per year is projected to increase to 23.6 million by 2030. Lung cancer is the leading cause of cancer deaths in Asia Pacific. China alone accounts for over 50% of all cancer cases in the region. Changes in lifestyle and socio-cultural factors are the leading causes of cervical cancer. Major countries affected by breast cancer in Asia Pacific are India, Thailand, and China.

Apart from cancer, a number of other diseases have shown increase in prevalence rates. Rise in prevalence of cancer, cardiovascular diseases, and diabetes; surge in sedentary lifestyle; and increase in geriatric population drive the need of better treatment options, which, in turn, propels the global AI in drug discovery market.

 Request for Analysis of COVID-19 Impact on AI in Drug Discovery Market –

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=82867

Software to Dominate Global Market

In terms of offering, the global AI in drug discovery market has been bifurcated into software and services. The software segment accounted for a major share of the global market in 2020. Factors such as less cost and time to market the drug, low failure rate, large number of software developers for drug discovery, and strong demand for software among big pharma & biotech companies and research institutes drive the software segment.

Use of Machine Learning Algorithms in Drug Discovery

Based on technology, the global AI in drug discovery market has been classified into machine learning and other technologies. The machine learning segment held significant share of the market in 2020. Machine learning algorithms that have been widely used in drug discovery include Random Forest (RF), Naive Bayesian (NB), and support vector machine (SVM) as well as other methods. ML algorithms and techniques are not a monolithic, homogeneous subset of AI.

 Buy AI in Drug Discovery Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=82867&ltype=S

Preference for Small Molecule Drugs

In terms of drug type, the global AI in drug discovery market has been split into small molecules and large molecules. The small molecules segment accounted for major share of the market in 2020. Small molecule drugs have some distinct advantages as therapeutics; most can be administered orally and pass through cell membranes to reach intracellular targets.

Oncology to Offer Lucrative Opportunities

Based on application, the global AI in drug discovery market has been categorized into oncology, infectious diseases, neurological disorders, rare diseases, metabolic diseases, cardiovascular diseases, and others. The oncology segment held significant share of the market in 2020. AI already plays a vital role in the early detection of cancer. Moreover, as treatments for cancer may vary for each patient, personalized medicine has proven to be an effective alternative for treating cancer. Artificial intelligence platforms designed to identify genetic mutations help oncologists design effective personalized treatment for patients.

Pharmaceuticals & Biotechnology Companies to Lead Global Market

Based on end user, the global AI in drug discovery market has been divided into pharmaceutical & biotechnology companies, contract research organizations, academics & research, and others. The pharmaceuticals & biotechnology companies segment accounted for major share of the market in 2020. The involvement of AI in the de novo design of molecules can be beneficial to the pharmaceutical sector, due to its various advantages, such as providing online learning and simultaneous optimization of the already-learned data as well as suggesting possible synthesis routes for compounds leading to swift lead.

Widespread Adoption of AI Systems in Healthcare Sector in U.S.

The global AI in drug discovery market has been segmented into five major regions North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2020. Rise in prevalence of lifestyle diseases and increase in healthcare expenditure are anticipated to boost the growth of the market in North America during the forecast period. According to the National Center for Chronic Disease Prevention and Health Promotion, six in 10 adults in the U.S. have a chronic disease, and there is widespread adoption of AI systems in the U.S., especially in the healthcare sector.

Competition Landscape

The global AI in drug discovery market is fragmented due to the presence of a large number of leading players. Key players operating in the global market include Exscientia, GNS Healthcare, Cloud Pharmaceuticals, Inc., Benevolent AI, PathAI, Inc., Berg Health, Atomwise, Insitro, Cyclica, BlackThorn Therapeutics, Insilico Medicine, Notable Labs, Standigm, Recursion Pharmaceuticals, and BioSymetrics.

Browse More Trending Reports by Transparency Market Research:

Valbenazine Market:

Valbenazine is a purified isomer of tetrabenazine drug, used to treat tardive dyskinesia which is a nervous system disorder. Dyskinesia refers to involuntary muscle movement that can range from slight tremor to uncontrollable movement of the entire body. Grimacing, tongue movements, lip smacking, lip puckering, pursing of the lips, etc. are the common effects of tardive dyskinesia. Valbenazine drug acts as a vesicular monoamine transporter 2 inhibitor, which is essentially an integral membrane protein, and decreases the level of dopamine in the body. Valbenazine decreases the level of monoamine neurotransmitters by preventing their storage in synaptic vesicles. The effect of this drug has been studied on pregnant women. Subsequently, it is not recommended to pregnant or breastfeeding women. The symptoms of tardive dyskinesia can be severe and are often persistent and irreversible. Both valbenazine and its active metabolite [+]-α-HTBZ have a half-life period of 15-22 hours and Tmax of 0.5 to 1 hr.

Choledocholithiasis Market:

A report on the global choledocholithiasis market by Transparency Market Research studies it from various angles. To that end it factors in the different market-specific and macro-fundamentals that are providing tailwinds and headwinds to the market. The report also segments the global choledocholithiasis market based on different parameters. It then studies the potential of each segment. Further, the report tries to unravel the competitive landscape by banking upon analytical tools such as SWOT Analysis and Porters Five Forces.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit Bhisey
Transparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Back to news